Strategic funding Develco Pharma Schweiz AG has recently secured additional financing of 10 million euros to bolster production and product development, indicating readiness for expanded manufacturing capacity and potential partnerships in high-impact formulations.

Rare disease focus The company specializes in difficult to make innovative formulations, including an oral prolonged-release ketamine program for treatment-resistant depression, suggesting sales opportunities in specialized CNS and novel therapeutics collaborations.

Joint venture activity Partnership with HMNC Brain Health on the Ketabon program demonstrates openness to co-development and strategic alliances, presenting opportunities for co-investment, licensing, or contract development/manufacturing arrangements.

Swiss manufacturing base Headquartered in Pratteln, Basel-Landschaft with a focused pharmaceutical manufacturing capability, offering a potential regional production partner for companies seeking Swiss GMP-compliant manufacturing, fill-finish, or scale-up services.

Modest but growing Revenue is in the low millions with a mid-teens funding level, signaling an opportunity to target efficiency-improvement projects, contract development/manufacturing services, and strategic collaborations to accelerate go-to-market for innovative formulations.